Live Breaking News & Updates on கட்டி திசு

Stay updated with breaking news from கட்டி திசு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Worldwide Genomic Cancer Panel and Profiling Industry to 2025 - Featuring Anchor, Bioarray Genetics and Burning Rock Among Others

Worldwide Genomic Cancer Panel and Profiling Industry to 2025 - Featuring Anchor, Bioarray Genetics and Burning Rock Among Others
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Miltenyi Biotec , Yourgene Elucigene , Agilent Dako , Qiagen Gmbh , Sysmex Inostics , Bristol Myers Squibb , Siemens Healthineers , Laura Wood , Academic Research Lab , Castle Biosciences Inc , Testing Lab , Public National , Central Lab , Technology Development , Singlera Genomics Inc , While Pharmaceutical Companies , Invitae Corporation , Genetron Holdings , Physician Office Lab , Research Testing Growth , Table Research Testing , Enzo Life Sciences Inc , Office Hours Call , Biodesix Inc , Datar Cancer Genetics ,

Worldwide Genomic Cancer Panel and Profiling Industry to 2025 - Featuring Anchor, Bioarray Genetics and Burning Rock Among Others

Worldwide Genomic Cancer Panel and Profiling Industry to 2025 - Featuring Anchor, Bioarray Genetics and Burning Rock Among Others
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Miltenyi Biotec , Yourgene Elucigene , Agilent Dako , Qiagen Gmbh , Sysmex Inostics , Bristol Myers Squibb , Siemens Healthineers , Laura Wood , Academic Research Lab , Castle Biosciences Inc , Testing Lab , Public National , Central Lab , Technology Development , Singlera Genomics Inc , While Pharmaceutical Companies , Invitae Corporation , Genetron Holdings , Physician Office Lab , Research Testing Growth , Table Research Testing , Enzo Life Sciences Inc , Office Hours Call , Biodesix Inc , Datar Cancer Genetics ,

Novartis Pharma AG: Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

At final analysis, study showed clinically relevant improvement in median overall survival with a difference of 11.7 months between arms (Hazard ratio (HR): 0.84 with 95% CI: (0.60, 1.17) (p=0.30 ....

United States , Isabella Zinck , Samir Shah , Julie Masow , Thomas Hungerbuehler , Sloan Simpson , Rachel Levine , Nuclear Medicine Through Innovation , Novartis Company , Elsevier Inc , Novartis External Communications , Exchange Commission , National Cancer Institute Surveillance , National Research Council , Institute Of Medicine , National Academies , National Cancer Institute , End Results , Advanced Accelerator Applications , Prescribing Information , Accelerator Applications , Positron Emission Tomography , Single Photon Emission Computed Tomography , Midgut Neuroendocrine , New Englandj Med , Product Characteristics ,

Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

Share this article
Share this article
EAST HANOVER, N.J., June 3, 2021 /PRNewswire/ Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera
® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus 30 mg octreotide LAR to 60 mg of octreotide LAR in patients with midgut neuroendocrine tumors. The previously reported primary analysis of the trial demonstrated a statistically significant improvement in progression free survival (PFS) (HR: 0.18 , p 0.0001)
3. In the final analysis of overall survival, a secondary objective of the trial, treatment with Lutathera resulted in a clinically relevant prolongation in median overall survival of 11.7 months [48.0 months (95%CI: 37.4-55.2) compared to the control arm (36.3 months (95%CI: 25.9-51.7)] ....

United States , Isabella Zinck , Samir Shah , Julie Masow , Thomas Hungerbuehler , Sloan Simpson , Rachel Levine , Prnewswire Novartis , Nuclear Medicine Through Innovation , Virtual Scientific Program , Novartis Company , Elsevier Inc , Novartis External Communications , Exchange Commission , National Cancer Institute Surveillance , National Research Council , Institute Of Medicine , Novartis Pharmaceuticals Corporation , National Academies , Scientific Program , National Cancer Institute , End Results , Advanced Accelerator Applications , Accelerator Applications , Positron Emission Tomography , Single Photon Emission Computed Tomography ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera ....

United States , Isabella Zinck , Samir Shah , Julie Masow , Thomas Hungerbuehler , Sloan Simpson , Rachel Levine , Nuclear Medicine Through Innovation , Virtual Scientific Program , Novartis Company , Elsevier Inc , Novartis External Communications , Exchange Commission , National Cancer Institute Surveillance , National Research Council , Institute Of Medicine , National Academies , Scientific Program , National Cancer Institute , End Results , Advanced Accelerator Applications , Prescribing Information , Accelerator Applications , Positron Emission Tomography , Single Photon Emission Computed Tomography , Midgut Neuroendocrine ,